Details for New Drug Application (NDA): 219692
NDA 219692 describes NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE, which is a drug marketed by Baxter Hlthcare Corp and Sagent and is included in three NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
The generic ingredient in NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE is norepinephrine bitartrate. There is one drug master file entry for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the norepinephrine bitartrate profile page.
Summary for 219692
| Tradename: | NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE |
| Applicant: | Sagent |
| Ingredient: | norepinephrine bitartrate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 219692
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) | ||||
| Approval Date: | Aug 11, 2025 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) | ||||
| Approval Date: | Aug 11, 2025 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
